This application requests support for personnel, operating expenses, and travel related to the conduct of Southwest Oncology Group (SWOG) cooperative clinical trials at the University of Kentucky. This support will serve to solidify, enhance and expand an already substantial contribution by this institution to the SWOG program in patient accessions, specifically the targeting of minority and underserved populations. The University of Kentucky Medical Center has established as its spearhead for oncology related clinical trials the Lucille Parker Markey Cancer Center. The Clinical Research Program of this center is the central node which supports the oncology related specialties in the performance of clinical research. This core facility of the cancer center, established in 1985, has undergone numerous extramural audits and was recently awarded (fall 1991) an Outstanding Achievement Award for data management excellence from the Southwest Oncology Group. In addition, we have received notification from the National Surgical Adjuvant Breast and Bowel Project (NSABP) that the University of Kentucky is a grant designee and recipient of the spring 1992 Exemplary Performance Award. A specific strength of this program has been the service of minority populations. Our own institutional activity and contributions supplied through other cooperative group outreach programs in our immediate region provide high quality tertiary care to the Appalachian region (a federally defined underserved population). We have recently been chosen by the Southwest Oncology Group to act as the parent organization for the cooperative group outreach programs serving minority populations in Atlanta, Georgia, through the Morehouse School of Medicine. The funds requested in this proposal will support the operations of the Clinical Research Program and consolidate the efforts of the various oncologic specialties of this center specifically as regards their participation in SWOG protocols.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA046136-08
Application #
2092087
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1988-01-01
Project End
1997-12-31
Budget Start
1995-01-01
Budget End
1995-12-31
Support Year
8
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Kentucky
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Lexington
State
KY
Country
United States
Zip Code
40506
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Hussain, Maha; Tangen, Catherine M; Berry, Donna L et al. (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368:1314-25
Mahadevan, Daruka; Unger, Joseph M; Spier, Catherine M et al. (2013) Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 119:371-9
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Petersdorf, Stephen H; Kopecky, Kenneth J; Slovak, Marilyn et al. (2013) A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121:4854-60
Gadgeel, Shirish M; Lew, Danika L; Synold, Timothy W et al. (2013) Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528. Cancer Chemother Pharmacol 72:1089-96
Nand, Sucha; Othus, Megan; Godwin, John E et al. (2013) A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia. Blood 122:3432-9
von Mehren, Margaret; Rankin, Cathryn; Goldblum, John R et al. (2012) Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 118:770-6
Tangen, Catherine M; Hussain, Maha H A; Higano, Celestia S et al. (2012) Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 188:1164-9

Showing the most recent 10 out of 93 publications